Fresh industry research highlights Bio-Rad Laboratories (BIO) as a key supplier across rapid diagnostic tests, transfer membranes, and proteomics tools, with rising sector demand feeding into recent market interest in the stock.
Recent sector reports and Bio-Rad Laboratories’ role across diagnostics and proteomics have arrived alongside a 90 day share price return of 22.99% and a 1 year total shareholder return of 19.24%. However, the 5 year total shareholder return of 50.36% is lower, which signals that longer term momentum has faded even as short term sentiment has improved.
Scan beyond Bio-Rad Laboratories and compare its diagnostics exposure with a curated group of peers across 33 healthcare AI stocks that are shaping the next wave of data-driven healthcare tools.
Bio-Rad Laboratories looks plugged into growing diagnostic and proteomics markets, and its share price has moved sharply in the last quarter. The real issue now is whether that quality is already fully reflected in today’s valuation.
Most Popular Narrative: 11% Overvalued
Bio-Rad Laboratories closed at $363.73, while the most followed valuation narrative pegs fair value at $329 based on a discount rate of 8.22%. That gap puts the emphasis squarely on whether modest growth and buybacks are enough to support the current share price.
Resilience and stable growth in consumables and reagents, demonstrated by high single-digit growth, especially in the face of delayed academic and instrument funding, are shifting Bio-Rad's sales mix toward higher-margin, recurring revenues, supporting overall profitability and cash flow stability.
Strategic operational actions, including lean initiatives, flexible supply chain management, and geographic diversification, have enabled Bio-Rad to offset tariff and reimbursement headwinds while benefiting from reduced regulatory trade risks, supporting improved operating margins and mitigating cost volatility.
See why 7 investors see Bio-Rad Laboratories as 11% overvalued.
Result: Fair Value of $329 (OVERVALUED)
Still, two pressure points hang over the Bio-Rad Laboratories story: softer instrument demand that weighs on margins, and policy shifts in key diagnostics markets like China.
Find out about the key risks to this Bio-Rad Laboratories narrative.
Another View on Bio-Rad Laboratories Valuation
On earnings multiples, Bio-Rad Laboratories tells a different story. The stock trades on a P/E of 43.7x, which is lower than the 48.3x peer average, yet well above the fair ratio of 17.2x that the market could move toward. That mix points to meaningful valuation risk if sentiment cools.
Investors comparing this pricing against other tools may want to scrutinize how much of today’s optimism is already embedded in the multiple, and how quickly that could unwind if earnings progress stalls. See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
Think the tone here feels cautious on Bio-Rad Laboratories? Move quickly from reading to testing the numbers yourself so you can decide where you stand, starting with this 1 important warning sign.
Looking for more investment ideas beyond Bio-Rad Laboratories?
If Bio-Rad Laboratories has you thinking more critically about price, quality, and risk, use that mindset to pressure-test a wider set of opportunities with structured screeners.
- Target resilient income streams by reviewing 8 dividend fortresses that combine higher yields with balance sheet checks and payout discipline.
- Hunt for quality at a discount through 32 high quality undervalued stocks that pair stronger fundamentals with pricing that still sits below many investors’ radars.
- Protect your downside first by scanning 32 resilient stocks with low risk scores that aim to keep volatility and financial red flags in check before you commit capital.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com